FOX04-DRI — Clinical Reference

**⚠ Educational reference only — not medical advice.** This article is for research and educational reference. Always consult your own physician before considering any peptide protocol. See the full Disclaimer at the end of this article. ## Introduction FOX04-DRI is a D-retro-inverso (DRI) peptide developed in the Demaria laboratory (Cell, 2017) as a senolytic agent — selectively eliminating senescent cells that accumulate with age and contribute to age-related pathology. The DRI configuration confers resistance to proteolytic degradation. Strictly investigational; no clinical indication is approved. ## Mechanism of Action Senescent cells depend on a FOXO4–p53 interaction to suppress p53-driven apoptosis. FOX04-DRI competitively disrupts this interaction, releasing p53 to translocate to mitochondria and initiate intrinsic apoptosis. Healthy non-senescent cells are largely spared. ## Research Indications Preclinical contexts include sarcopenia, frailty, fibrotic disease, radiation injury, and age-associated organ dysfunction. Reductions in senescence markers (p16INK4a, SA-β-gal) and functional improvements have been reported in murine models. Clinical-grade human data are not yet established. ## Reconstitution Typical 10 mg lyophilized vial: add **2 mL of bacteriostatic water**, swirl gently. Final concentration **5000 mcg/mL (5 mg/mL)** — each 0.2 mL (20 units on a U-100 insulin syringe) delivers 1 mg. ## Dosing Protocol (research literature) Senolytic strategy favors **pulse dosing** consistent with the "hit-and-run" pharmacology of the class — typically **5 mg subcutaneously every 3 days × 3 pulses**, then reassess at 4–6 weeks. Continuous daily dosing is not the published model. Some protocols repeat the 3-pulse cycle quarterly. ## Administration Subcutaneous injection into abdominal fat, rotating sites. Pulse spacing of at least 48–72 hours. ## Storage & Handling Lyophilized: refrigerate (2–8°C); freeze (–20°C) for long-term storage beyond 30 days. Reconstituted: refrigerate; stable approximately **7–14 days**. Protect from light. ## Side Effects Human safety data are not established. Animal work has reported transient inflammatory effects following senescent-cell clearance. Monitor closely for any acute reaction in the 24–72 hours following each pulse. ## Contraindications Pregnancy, lactation, active malignancy, acute illness, and any uncontrolled inflammatory condition. ## Monitoring Baseline CBC, comprehensive metabolic panel, CRP, and frailty/functional measures appropriate to the cohort. Re-measure CRP at 72 hours post-pulse and functional measures at 6 weeks. ## Disclaimer **This article is for informational and research-reference purposes only.** Nothing in this document constitutes medical advice, a prescription, or a recommendation from a physician. The reconstitution, dosing, and protocol information above reflects ranges commonly cited in published research and clinician-directed protocols — it is provided as reference material only, not as instructions, an endorsement of off-label use, or a substitute for individualized medical evaluation. **Customers should do their own research and consult their own physician** before considering any peptide protocol. Whether a given compound is appropriate for an individual — and at what dose, for what duration, and alongside what monitoring — is a decision that only a licensed clinician with knowledge of that individual's medical history, current medications, and conditions can make. The platform and the author make no claim that any compound described here is safe, effective, or appropriate for any particular person or purpose, and accept no responsibility for outcomes arising from self-directed use of the information.